Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARSiFAL-pilot: BAY1067197 in Chronic Systolic Heart Failure
NCT02040233Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of neladenoson bialanate in systolic heart failure (HFrEF), sponsored by Bayer. Started Jan 2014; status: completed.
02
Drugs
neladenoson bialanate
03
Conditions
systolic heart failure (HFrEF)
Beyond the preview
Go deeper on NCT02040233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040233.